Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M
Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million in common shares to the public through appointed agents Cantor Fitzgerald Canada Corp.
